جستجوی استاد راهنمای دانشگاهی

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

• Mass Spectrometry
• Proteomics
• Systems Biology
• +۶ مورد دیگر

Jeppe Lund Nielsen is a Professor in the Department of Chemistry and Life Sciences at the Faculty of Engineering and Science, Aalborg University, Denmark. His research lies at the intersection of microbial ecology, genomics, and environmental biotechnology, with a strong focus on sustainable solutions for wastewater treatment, anaerobic digestion, and environmental monitoring. His primary research interests include Microbial Ecology, Functional Ecology, Genomics, Molecular and Technical Microbiology, Anaerobic Digestion, Metagenomics, and eDNA Metabarcoding . He applies molecular tools to understand microbial community dynamics in engineered and natural systems, particularly in wastewater and marine environments. His work contributes to the UN Sustainable Development Goals related to clean water, sustainable cities, and climate action. The recent publication trends reflect a strong emphasis on environmental applications of microbiome science, including nitrogen cycling in wastewater, bioaerosol exposure in workers, eDNA-based biodiversity monitoring, and valorization of waste streams through biotechnology. His articles frequently appear in high-impact environmental and microbiological journals and demonstrate interdisciplinary collaboration across engineering, ecology, and public health. Among his notable scientific contributions are leadership roles in significant research projects such as the AAU Bubble Project (Power2Proteins), JAMBO seabed impact study, and investigations into biotechnological pesticides. He has also contributed to public discourse through media engagement on topics like pesticide regulation and environmental innovation. Professor Nielsen has supervised PhD students, including M. Eskeldsen, and is actively involved in grants and collaborative research across Europe. He is a key member of research teams focused on environmental microbiology, wastewater biotechnology, and marine impact assessments. His lab integrates molecular biology, bioinformatics, and environmental engineering to address pressing sustainability challenges.

• Microbial Ecology
• Functional Ecology
• Genomics
• +۱۰ مورد دیگر

Antti Poso is a Professor of Drug Design at the University of Eastern Finland (Kuopio), affiliated with the School of Pharmacy under the Faculty of Health Sciences. His research focuses on computer-aided molecular design, particularly targeting anti-cancer drugs and anti-microbials. Key projects include the EDCMET project (2019–2024) and the GeneCellNano Flagship (2020–2028). He leads the Molecular Modeling and Drug Design Research Group, specializing in QSAR analysis, kinase inhibition profiling, and systems-level drug response modeling. Recent work includes studies on SARS-CoV-2 inhibitors, endocrine disruptors, and bacterial pathogenesis. His findings bridge chemical structure with biological outcomes, leveraging computational tools like CCA and molecular dynamics simulations. Collaborations span medicinal chemistry, pharmacology, and systems biology, contributing to both academic and applied drug discovery efforts. Education: Not explicitly stated in texts; assumed to hold advanced degrees in pharmacy or chemistry. Research Themes: Drug design, molecular modeling, QSAR, computational biology, and anti-infective agents. Key Contributions: Over 150+ publications, including influential works on chemoinformatics-driven drug response analysis and structure-based inhibitor design. Publications highlight advancements in kinase inhibitors, anti-microbial strategies, and viral hijacking mechanisms. His work emphasizes translating computational insights into therapeutic solutions for cancer, infectious diseases, and metabolic disorders.

• Drug Design
• Molecular Modeling
• Anti-Cancer Drugs
• +۳ مورد دیگر

Huiyan Li, PhD, P.Eng., is an Associate Professor in the Department of Biomedical Engineering at the University of Guelph. Her research focuses on developing micro/nanoscale biosensors and lab-on-a-chip technologies for cancer diagnostics and personalized medicine. Dr. Li holds a Ph.D. in Biomedical Engineering from McGill University and completed postdoctoral training at Harvard Medical School/Massachusetts General Hospital. Her multidisciplinary research integrates biosensing, micro/nanofabrication, bio-optics/electronics, and computational tools to study cancer molecular complexity. Current openings exist for M.A.Sc. students interested in biosensing research. Key research areas include extracellular vesicle analysis, multiplexed immunoassays, magnetic/nanoparticle-enhanced bioassays, and graphene-based biomedical sensors. Recent work emphasizes point-of-care diagnostics and enhanced protein detection via novel material integration. Teaching responsibilities include ENGG 6301 (Advanced Micro/Nano Biotechnology) and undergraduate courses in bio-instrumentation and biomedical signal processing. Her work spans biomaterials classification, microfluidic systems, and antimicrobial nanocomposite development. Research outputs emphasize scalable microarray formats, EV-based biomarker discovery, and sensor sensitivity enhancement through nanomaterial innovations. Current projects address EV concentration measurement, 3D antibody microarrays, and magnetic-responsive hydrogel discs for bioassay improvements.

• Biosensors
• Lab-on-a-chip Technologies
• Cancer Diagnostics
• +۴ مورد دیگر

Vijini Mallawaarachchi is a Research Fellow in Bioinformatics at Flinders University's Flinders Accelerator for Microbiome Exploration (FAME). His research focuses on developing computational methods for metagenomic analysis, particularly viral genome recovery from metagenomes. He holds a PhD in Computer Science from the Australian National University (2022) and a BSc in Computer Science and Engineering (Honours) from the University of Moratuwa, Sri Lanka (2018). Education: Doctor of Philosophy (Computer Science), Australian National University, 2018–2022 Bachelor of Science (Computer Science & Engineering, Honours), University of Moratuwa, 2014–2018 Research Interests: Metagenomics, algorithms for genome recovery, bacteriophage discovery, machine learning applications in bioinformatics, and software engineering for computational biology. His work emphasizes leveraging assembly graphs and computational models to analyze microbial communities and viral genomes. Grants & Awards: 2025: National Computational Merit Allocation Scheme Grant (Co-CI) - A$412,000 2025: ARC Discovery Projects Grant (Co-CI) - A$685,781 2024: Outstanding PhD Thesis Award (ABACBS) 2023: Australian Society for Microbiology Early Career Award Professional Engagement: Active member of ISMB, ISVM, ACM, IEEE, ABACBS, ASM, and RSE AU/NZ. Supervises HDR and Honours students in bioinformatics and computational biology. Labs & Tools: Leads projects at FAME, developed tools like GraphBin, Phables, and ConDiGA for metagenomic analysis. Collaborates on open-source initiatives like the cogent3 Python APIs.

• Metagenomics
• Bioinformatics
• Bacteriophages
• +۳ مورد دیگر

Dr. Heather Murray is a Cancer Institute NSW Early Career Research Fellow at the University of Newcastle, affiliated with the School of Biomedical Sciences and Pharmacy. She holds dual roles as a Lecturer and Postdoctoral Researcher, focusing on proteomics and phosphoproteomics to uncover therapeutic targets in acute myeloid leukemia (AML). Her work combines genomic, proteomic, and clinical approaches to address treatment resistance and precision medicine in blood cancers. Education: PhD in Medical Biochemistry (University of Newcastle, 2020), MPhil, BSc (Hons) in Biomedical Sciences, and BSc in Biological Sciences, all from the University of Newcastle. Research Interests: Proteomic characterization of leukemia subtypes, DNA repair mechanisms, and drug resistance pathways. Her lab uses phosphoproteomics to identify synergistic drug combinations targeting oncogenic pathways like FLT3 and KIT mutations. Key Collaborations: Works with clinicians like Associate Professor Anoop Enjeti and researchers at Hunter Medical Research Institute. Partnerships include institutions like the University of Southern Denmark and QIMR Berghofer. Grants & Funding: Secured over $2M in funding, including a 2022 Cancer Institute NSW Fellowship, BarbeCURE grants, and philanthropic support from organizations like the McDonald Jones Charitable Foundation. Supervision: Mentors 6 current PhD students on topics like venetoclax resistance, breast cancer biomarkers, and ex vivo AML models. Supervision history includes 6 completed Honours projects. Labs/Teams: Leads the Molecular Oncology group under Associate Professor Nikki Verrills. Member of the HMRI Precision Medicine Program and University of Newcastle ECR committees.

• Proteomics
• Phosphoproteomics
• Acute Myeloid Leukemia (AML)
• +۳ مورد دیگر

Hartmut Michel is a Scientific Member and Director at the Max Planck Institute of Biophysics in Frankfurt, Germany, where he leads the Department of Molecular Membrane Biology. He has held this position since 1987 and has also served as an Adjunct Professor at the University of Frankfurt since 1989. Michel received his PhD in Biochemistry from the University of Wuerzburg in 1977 and completed postdoctoral work there before joining the Max Planck Institute of Biochemistry as a research associate. Michel's research focuses on membrane proteins, particularly in the areas of structural biology, biochemistry, photosynthesis, and respiratory complexes. His work has centered on understanding the structure and function of membrane proteins, especially cytochrome c oxidase and photosynthetic reaction centers. He pioneered techniques for membrane protein crystallization and has made significant contributions to understanding electron transfer processes and proton pumping mechanisms in respiratory enzymes. His publication record spans over four decades, with recent work focusing on cryo-EM structural analysis of membrane proteins including cytochrome bd oxidases, ABC transporters, and photosynthetic complexes. The research demonstrates a consistent trajectory from fundamental structural studies toward understanding functional mechanisms and applications in areas like antibiotic development and bioenergetics. Scientific Awards 1986 Leibniz Prize of the German Research Foundation 1988 Otto Bayer Prize (with Johann Deisenhofer) 1988 Nobel Prize in Chemistry (with Johann Deisenhofer and Robert Huber) 2008 Keilin Medal of the British Biochemical Society Honorary doctorates from the Universities of Wuerzburg and Bologna Michel has maintained an active research program with numerous collaborations across Europe and internationally. His laboratory has developed innovative approaches for membrane protein expression, purification, and structural characterization. The team has made significant contributions to understanding the structure-function relationships in respiratory chain components and photosynthetic apparatus. His department at the Max Planck Institute serves as a leading center for membrane protein research, with specialized facilities for protein crystallization, cryo-electron microscopy, and functional characterization of membrane proteins. The research has implications for understanding fundamental biological energy conversion processes and developing new therapeutic approaches targeting membrane proteins.

• Membrane Proteins
• Structural Biology
• Biochemistry
• +۵ مورد دیگر

Mikhail Gelfand is a Full Professor and Director of the Center for Molecular and Cellular Biology at Skolkovo Institute of Science and Technology (Skoltech), where he also serves as Vice President for Biomedical Research. His distinguished career spans multiple prestigious institutions including Lomonosov Moscow State University and the Higher School of Economics. His educational background includes: 1985: MSc in mathematics (functional analysis) 1993: PhD in physics-mathematics (biophysics) 1998: DSc in biology (molecular biology) 2007: full professor (bioinformatics) Professor Gelfand's research focuses on molecular evolution, comparative genomics, systems biology, and metagenomics. His work examines eukaryotic processes including alternative splicing, mRNA editing, and chromatin structure, as well as bacterial genome evolution and transcription regulation. His lab combines data on three-dimensional chromatin structure, epigenetic states, and gene expression to obtain an integrated view of genome functioning across diverse organisms from humans to amoebae. One major research direction focuses on the evolution of transcript splicing and editing, while comparative analysis of bacterial genomes yields functional annotations of novel enzymes, transporters, and transcription factors. His recent publications demonstrate a strong focus on RNA editing in cephalopods, bacterial genome analysis, and computational approaches to understanding chromatin structure. The work spans molecular biology, evolutionary biology, and bioinformatics, with particular emphasis on how RNA editing contributes to adaptation and molecular evolution across metazoans. His research shows how edited adenines are more frequently substituted with guanine in evolution than their unedited counterparts, suggesting RNA editing may enhance adaptation. His notable awards include: The President of Russian Federation's Award for Young Doctors of Science (2000) The "Best Scientist of the Russian Academy of Sciences" award (2004) A. A. Baev Prize in Genomics and Genoinformatics (2007) Member of Academia Europaea (2010) As Director of the Center for Molecular and Cellular Biology, Professor Gelfand leads a research group that combines computational and experimental approaches to study genome function and evolution. His lab's work has significant implications for understanding molecular mechanisms of evolution and adaptation across diverse biological systems, from bacteria to complex eukaryotes. His research on metagenomics extends to practical applications in areas including coral disease, aphids, and oil wells.

• molecular evolution
• comparative genomics
• systems biology
• +۷ مورد دیگر

Yulong Wei is a Researcher in the Department of Microbial Pathogenesis at Yale School of Medicine. His work focuses on understanding viral persistence mechanisms, particularly in HIV-1 and SARS-CoV-2, using cutting-edge genomic and immunological approaches. He explores how host cellular environments influence viral integration, reservoir formation, and immune evasion. Research interests include: HIV reservoir dynamics and latency mechanisms Host-pathogen interactions in viral persistence Single-cell multiomics analysis of viral infections Antiviral drug discovery and repurposing Ribosomal adaptation and translation mechanisms in bacteria Recent work highlights his contributions to understanding how interferon signaling and chromatin structure affect HIV integration sites, as well as computational studies of griseofulvin's potential in combating SARS-CoV-2. He has also investigated evolutionary genomic signatures in microbes related to translation efficiency and environmental adaptation. His lab is part of the Yale School of Medicine's broader efforts in microbial pathogenesis and infectious disease research, with a focus on translational applications for persistent viral infections.

• HIV Research
• Virology
• Immunology
• +۳ مورد دیگر

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

• Molecular Oncology
• Precision Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Amar U. Kishan, MD , a tenure Professor at the David Geffen School of Medicine, UCLA , serves as Executive Vice Chair for the Department of Radiation Oncology and as Chief of the Genitourinary Service since 2019. His clinical expertise focuses on radiation treatment of prostate and bladder cancers , with pioneering work in stereotactic body radiation therapy (SBRT) and image-guided radiotherapy . Dr. Kishan graduated magna cum laude from Harvard Medical School after dual BA degrees at UC Berkeley in Molecular and Cell Biology and Public Health, followed by residency at UCLA and internship at Scripps Mercy Hospital . Education : Harvard Medical School (MD, 2012), UC Berkeley (BA in Molecular/Cell Biology & Public Health) Awards : Leonard Tow Humanism in Medicine (2021), UCLA Exceptional Physician (2024), Super Doctors® Rising Stars (2020-2024) Dr. Kishan leads translational research connecting radiation oncology with genitourinary cancer biology. His 310+ publications in journals like JAMA , Lancet Oncology , and European Urology emphasize radiation technology innovations , including MRI-guided SBRT and adaptive radiation therapy. Key trials he spearheads include ILLUSION (CT-guided SBRT) and HEATWAVE (apalutamide + SBRT). Major funding sources include National Institutes of Health , Department of Defense , and Prostate Cancer Foundation . His work has redefined prostate cancer treatment paradigms , demonstrating that high-dose radiation can match surgery in aggression cases, while multi-modal approaches improve survival rates. Dr. Kishan also contributes to re-irradiation protocols and radioresistance proteogenomics , advancing precision oncology. Key Grants : NIH, DoD, PCF, ASTRO Clinical Trials : ILLUSION, HEATWAVE, PET imaging-based radiation targeting

• Translational Research
• Clinical Outcomes Research
• Advanced Radiation Technologies
• +۵ مورد دیگر

Michal Bassani-Sternberg is an Assistant Professor on conditional pre-tenure at the Faculty of Biology and Medicine, University of Lausanne (UNIL), and an Assistant Member at the Ludwig Institute for Cancer Research, Lausanne. She leads the Antigen Discovery Group and the Immunopeptidomics Unit at the Center for Experimental Therapies, Department of Oncology, UNIL-CHUV. Her work bridges proteogenomics, mass spectrometry, and computational biology to advance personalized cancer immunotherapy. Her educational background includes a Bachelor, Master, and Doctorate in Biology from the Technion – Israel Institute of Technology, Haifa, all earned with Cum Laude distinction. She completed postdoctoral training at the Technion and the Max Planck Institute for Biochemistry, Germany, in the group of Prof. Matthias Mann. Dr. Bassani-Sternberg's research focuses on identifying cancer-specific Human Leukocyte Antigen (HLA) ligands to guide the development of personalized immunotherapies. Her group develops cutting-edge proteogenomic and mass spectrometry-based immunopeptidomics approaches to discover tumor-associated antigens, neoantigens, and non-canonical peptides. A key contribution is the development of NeoDisc, a continuous bioinformatics pipeline that integrates genomics, transcriptomics, and immunopeptidomics data for direct neoantigen identification in clinical trials. Her recent publications, appearing in high-impact journals such as Nature , Nature Biotechnology , Immunity , and Nature Cancer , reflect a strong trend in integrating multi-omics data to understand tumor immunogenicity, T cell responses, and antigen presentation dynamics. Her work increasingly incorporates machine learning to improve neoantigen prediction and TCR specificity inference. She has been recognized with the Pfizer Research Prize in 2021 for her contributions to immuno-oncology. Pfizer Research Prize (2021) Dr. Bassani-Sternberg leads an active research group involved in phase I clinical trials for personalized cancer vaccines and adoptive T cell therapies. Her lab is supported by major grants from the Swiss Cancer League, Swiss National Science Foundation, and ISREC Foundation. She mentors doctoral and postdoctoral researchers and collaborates extensively within the Lausanne immuno-oncology ecosystem, including CHUV and Ludwig Lausanne. Her lab, the Bassani-Sternberg Lab, is part of the Department of Oncology’s research platforms and focuses on immunopeptidomics, antigen discovery, and the development of analytical tools for personalized immunotherapy.

• Cancer Immunotherapy
• Immunopeptidomics
• Proteogenomics
• +۷ مورد دیگر

Emanuel Petricoin is a Professor and Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University's School of Systems Biology, a position held since 2005 with prior leadership at the FDA-NCI Clinical Proteomics Program (1993-2005). His academic affiliation spans proteomics, molecular medicine, and precision oncology within GMU's research ecosystem. His educational background includes: Ph.D. in Microbiology from the University of Maryland, College Park (1990) Dr. Petricoin pioneers clinical proteomics for personalized therapy and biomarker discovery, with seminal work in cancer signaling pathways, tumor microenvironment analysis, and diagnostic assay development. His research integrates proteogenomics, phosphoproteomics, and functional protein analysis to address therapeutic resistance in breast and pancreatic cancers. As a translational scientist, he bridges laboratory innovation with clinical implementation through FDA-regulated platforms. Analysis of his 2024-2025 publications reveals dominant themes in proteogenomic tumor characterization, KRAS/HER2 pathway dynamics, and biomarker-guided immunotherapy. Key trends include spatial proteomics of tumor heterogeneity, extracellular vesicle-mediated signaling, and quantitative assessment of drug targets for precision oncology decision-making. The work consistently emphasizes clinical applicability through CLIA-certified assays and molecular tumor boards. His scientific recognition includes: University Professorship at George Mason University NIH Director’s Award FDA Distinguished Scientist Award 2015 Innovator of the Year Award GAP50 Top Virginia Entrepreneurs Nifty 50 Award American Society of Cytopathology Basic Research Award Roche Diagnostics/CLAS Distinguished Scientist Award Harvard University Leading Edge Award Dr. Petricoin drives research commercialization as co-founder of four biotech firms (Theranostics Health, Ceres Nanosciences, C-4 Diagnostics, Perthera) and co-inventor of 40+ patents. His editorial leadership spans Proteomics, Cancer Epidemiology Biomarkers and Prevention, and other high-impact journals. He actively shapes national initiatives as a HUPO founding member and Virginia Health Research Biosciences Corporation board representative. The CAPMM under his co-direction serves as a national hub for clinical proteomics, specializing in reverse-phase protein array (RPPA) technology, laser capture microdissection, and biomarker validation for direct patient care applications. The center integrates multi-omic data to advance personalized cancer therapy through industry partnerships and clinical trial support.

• Proteomics
• Molecular Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Dennis C. Sgroi, MD, is Professor of Pathology at Harvard Medical School and Executive Vice-Chair of Pathology at Massachusetts General Hospital (MGH), where he also serves as Director of Breast Pathology. He leads the Sgroi Laboratory within the Molecular Pathology Unit and the Krantz Family Center for Cancer Research at MGH. Education & Training: MD, University of Connecticut School of Medicine Residency, Massachusetts General Hospital Fellowship, Massachusetts General Hospital Board certified: Anatomic & General Pathology, American Board of Pathology Research Focus: Dr. Sgroi’s laboratory integrates multi-omics technologies to discover and validate molecular biomarkers that predict breast-cancer recurrence and therapeutic response. Core projects include the clinically-adopted Breast Cancer Index (BCI) assay (HOXB13/IL17RB), deciphering HOXB13-mediated tumor-microenvironment remodeling in ER-positive and triple-negative breast cancer, and developing combinatorial therapies targeting HOXB13/ERBB2 co-amplified tumors with BRCA1 loss. Clinical Impact & Guidelines: The BCI biomarker has been prospectively validated in multiple randomized trials (NSABP-B-42, Trans-aTTom) and is now incorporated into NCCN and ASCO treatment guidelines for extended adjuvant endocrine therapy in post-menopausal women with ER-positive breast cancer. Scientific Awards & Honors: While individual awards are not enumerated in the supplied text, the sustained funding of ~ $19 million in annual direct research costs attests to national peer-review recognition. Research Team & Collaborations: The Sgroi Lab includes post-doctoral fellows, graduate researchers, and staff scientists such as Marinko Sremac, PhD. Collaborative networks span Dana-Farber/Harvard Cancer Center Breast Cancer and Cancer Genetics Programs, NRG Oncology, and international genomic consortia.

• Breast Cancer Pathology
• Molecular Oncology
• Translational Cancer Research
• +۴ مورد دیگر

Gunther Zupanc is a Professor of Biology at Northeastern University's College of Science. His research focuses on neural mechanisms underlying structural plasticity in adult vertebrate nervous systems, particularly adult neurogenesis and neuronal regeneration in teleost fish. He leads the Laboratory of Neurobiology, combining cellular, neuroanatomical, and behavioral approaches to study neuron replacement and network dynamics. His work explores evolutionary factors limiting neurogenesis in mammals versus non-mammalian species, aiming to inform regenerative therapies for neural injuries and diseases. Education details are not explicitly provided in the text, but his expertise spans behavioral neurobiology, comparative neurobiology, and regenerative biology. Key research themes include stem cell populations in spinal cord regeneration, spatiotemporal neurogenesis patterns, and transcriptomic analysis of knifefish neural systems. His articles emphasize interdisciplinary methods bridging genetics, proteomics, and computational modeling. Zupanc’s research has been featured in collaborative studies with institutions like the Agar Lab, focusing on transcriptome validation in electrosensory systems. He recently advised doctoral candidates Meining Carly Ching, Tommy Tashjian, and Antonia Vitalo, who successfully defended their dissertations in Fall 2019. His lab is located in the Mugar Life Sciences Building, Room 134, Boston.

• Behavioral Neurobiology
• Comparative Neurobiology
• Developmental Neurobiology
• +۳ مورد دیگر